- Erasca Inc (NASDAQ:ERAS) announced preliminary Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumor settings.
- A retrospective pooled analysis of all trials evaluating ERAS-007 or ERAS-601 in advanced solid tumors included Erasca’s ongoing HERKULES-1 and FLAGSHP-1 trials and Asana BioSciences’ previously completed ASN007-101 trial.
- Key findings from the retrospective pooled interim analysis of ERAS-007 and ERAS-601 show that 23% (6/26) of patients with RAS/MAPK-altered non-colorectal cancer (CRC) solid tumors responded (2 confirmed and four unconfirmed PRs) to single agent ERAS-007 or ERAS-601.
- 44% (4/9) with a subset of BRAF-driven non-CRC solid tumors responded (1 confirmed and three unconfirmed PRs).
- ERAS-007 and ERAS-601 had favorable safety and tolerability monotherapy profiles with largely non-overlapping treatment-related adverse events that support combination development.
- Recently, Erasca announced a partnership with The University of Texas MD Anderson Cancer Center to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway as either single-agent or combination therapies.
- Under the terms of the five-year agreement, collaborative preclinical and clinical studies will be conducted in NSCLC and GI malignancies.
- The company will initiate a dose escalation trial for ERAS-007 in combination with ERAS-601 in the first half of 2023.
- Price Action: ERAS shares are down 17.07% at $7.80 on the last check Thursday.
Vertex Announces Results From Pivotal Trials Of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment For Cystic Fibrosis
– Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older –– Results were more
